MarketScreener Homepage > Equities > Tokyo Stock Exchange > Chugai Pharmaceutical Co., Ltd. 4519 JP3519400000

Report

End-of-day quote Tokyo Stock Exchange - 10/23
4281	JPY		+3.01%

10/23

CHUGAI PHARMACEUTICAL : Announces 2020 3rd Quarter Results

10/22

Japan stocks end lower as firmer yen, U.S. political uncertainty weigh

10/22

Japanese shares fall on rising yen, U.S. political uncertainty

Summary

Quotes 5-day view End-of-day quote.

End-of-day quote Tokyo Stock Exchange

10/19/2020	10/20/2020	10/21/2020	10/22/2020	10/23/2020	Date
4393	4353	4305	4156	4281	Last
1321900	1301900	1591700	1581700	2761200	Volume
+1.71%	-0.91%	-1.10%	-3.46%	+3.01%	Change

Financials

Sales 2020	760 B 7 253 M 7 253 M
Net income 2020	211 B 2 018 M 2 018 M
Net cash position 2020	403 B 3 844 M 3 844 M
P/E ratio 2020	33,2x
Yield 2020	1,19%

Sales 2021	828 B 7 904 M 7 904 M
Net income 2021	246 B 2 347 M 2 347 M
Net cash position 2021	496 B 4 738 M 4 738 M
P/E ratio 2021	28,2x
Yield 2021	1,54%

Capitalization	7 037 B 67 163 M 67 191 M
EV / Sales 2020	8,73x
EV / Sales 2021	7,90x
Nbr of Employees	7 394
Free-Float	37,7%

More Financials

Company

Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).

Sector

Pharmaceuticals

Calendar

12/29

More about the company

Notations Surperformance© of Chugai Pharmaceutical Co., Ltd.

Trading Rating :

Investor Rating :

More Ratings

All news about CHUGAI PHARMACEUTICAL CO., LTD.

10/23	CHUGAI PHARMACEUTICAL : Announces 2020 3rd Quarter Results	AQ
10/22	Japan stocks end lower as firmer yen, U.S. political uncertainty weigh	RE
10/22	Japanese shares fall on rising yen, U.S. political uncertainty	RE
10/21	PTC Therapeutics Says Evrysdi Approved in Brazil, Japan NDA Filed	DJ
10/20	Chugai and Welby Launch a Treatment Support Personal Health Record Service fo..	AQ
10/19	CHUGAI PHARMACEUTICAL CO., LTD. : quaterly earnings release
10/16	CHUGAI PHARMACEUTICAL : Files a New Drug Application for Risdiplam as the First ..	AQ
10/07	CHUGAI PHARMACEUTICAL : enters into a License Agreement for 's Antibody Engineer..	AQ
10/05	CHUGAI PHARMACEUTICAL : Files for Expanded Use of FoundationOne CDx Cancer Genom..	AQ
10/05	CHUGAI PHARMACEUTICAL : Files for Expanded Use of FoundationOne CDx Cancer Genom..	AQ
09/28	CHUGAI PHARMACEUTICAL : Obtains Approval for Additional Indication of Tecentriq ..	AQ
09/10	Chugai and Takeda to Join a Clinical Collaboration for Global Phase III Studi..	AQ
09/10	Chugai and NTT DATA Complete Demonstration of AI-based Clinical Trial Efficie..	AQ
09/10	CHUGAI PHARMACEUTICAL : New Data of Chugai's Enspryng (Satralizumab) on Risk and..	BU
09/02	CHUGAI PHARMACEUTICAL : Introduces LINE WORKS by WORKS MOBILE Japan for 2,400 Em..	AQ

More news

News in other languages on CHUGAI PHARMACEUTICAL CO., LTD.

10/19	CHUGAI PHARMACEUTICAL CO., LTD. : Veröffentlichung des Quartalsergebnisses
10/19	CHUGAI PHARMACEUTICAL CO., LTD. : publication des résultats trimestriels
10/16	TOUR DU MONDE DES INDICES : De l’équilibrisme à l’or bleu
10/15	ROCHE : Chugai dépose une demande d'homologation pour Risdiplam
09/25	ROCHE : extension d'homologation pour Tecentriq et Avastin au Japon

More news

Stock Trading Strategies

	CHUGAI PHARMACEUTICAL CO., LTD. - 05/18
The trend should regain control

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Chart CHUGAI PHARMACEUTICAL CO., LTD.

Duration : Period :

Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.

	Short Term	Mid-Term	Long Term
Trends	Bearish	Bearish	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	12
Average target price	4 939,75 JPY
Last Close Price	4 281,00 JPY
Spread / Highest target	63,5%
Spread / Average Target	15,4%
Spread / Lowest Target	-13,6%

Consensus

EPS Revisions

More Estimates Revisions

Managers

Name	Title
Tatsuro Kosaka	Chairman & Chief Executive Officer
Osamu Okuda	President, COO & Representative Director
Itagaki Toshiaki	CFO, Manager-Information Technology & Accounting
Hisafumi Okabe	Senior Executive Officer & Head-Research
Junichi Nezu	Executive Officer, GM-Research & Development

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

CHUGAI PHARMACEUTICAL CO., LTD.	27.41%	67 163



JOHNSON & JOHNSON	-0.43%	382 391
ROCHE HOLDING AG	-5.29%	280 884
PFIZER INC.	-2.55%	212 162
MERCK & CO., INC.	-12.23%	201 909
NOVARTIS AG	-16.78%	185 999

More Results